In the San Raffaele Bone Marrow Transplantation Unit, from 2010 to 2015, we retrospectively identified 66 patients that received posaconazole oral suspension (200 mg orally, 8-hourly) as primary (n = 43) or secondary (n = 23) antifungal prophylaxis 10 after allo-HSCT. All patients received supportive care and prophylaxis against opportunistic infections in accordance with the institutional guidelines. IFI were classified according to the definitions from EORTC/MSG Consensus Group. 11 Descriptive statistics were used to summarize patient characteristics and clinical outcomes. We performed either χ 2 -test for independence or Fisher's exact test to examine the relation between overall survival, posaconazole levels, IFI and clinical variables. Odds ratios (OR), 95% confidence intervals (CI) and P-values were calculated. The statistical significance was determined at P o0.05. All statistical analyses were performed using IBM SPSS (Version 20.0, IBM Corp., Armonk, NY, USA).
Patients, donors and graft characteristics are provided in Table 1 . Median age at HSCT was 55 years (range 17-74) and 39 patients were males. The majority of patients were affected by acute leukemia (67%), not in remission at the time of allo-HSCT (55%), and received HSCT from haploidentical donor (50%), preceded by a myeloablative conditioning regimen. Graft source was mainly PBSCs (89%). A previous HSCT was reported in 30% of the patients (12 autologous and 8 allogeneic HSCT). The time from diagnosis to allogeneic HSCT was more than 12 months in 38 patients (58%). All patients were considered at high risk for developing post-transplant IFI according to GITMO criteria. GvHD prophylaxis consisted of sirolimus and mycophenolate mofetil, which were started on day +5. Sirolimus was monitored twice weekly in order to maintain a target therapeutic plasma level of 5-14 ng/mL, whereas posaconazole was controlled weekly in serum during the first 2 months of coadministration. Posaconazole dose was adjusted as required to maintain trough serum levels within the therapeutic range (40.5 mL/L, according to the majority of literature and center guidelines). 5 However, some recent studies identified a number of breakthrough fungal infections in patients with posaconazole concentrations between 0.5 and 0.7 mL/L, suggesting a different concentration target of 0.7 mL/L for antifungal prophylaxis. 5 Median follow-up was 357 days (range 43-1884) after HSCT. Neutrophil engraftment occurred within a median of 18 days (range 10-30). Acute GvHD occurred in 36 patients, grade II-IV in 19 and gut involvement in 12 cases. Twenty-four patients developed chronic GvHD, type classic in 11 and overlap in 13 cases; gut involvement was reported in 8 chronic GvHD cases.
Posaconazole administration was given for a median of 221 days (range 13-966). Thirty-two patients (49%) received posaconazole during engraftment phase, whereas 28 (42%) and 19 (29%) patients for IFI prophylaxis in the setting of acute or chronic GvHD, respectively.
Concomitant administration of posaconazole and sirolimus occurred in 49 patients (74%). A 55-70% steady-state daily dose reduction of sirolimus was necessary in 19 of these patients after posaconazole introduction. Alternatively, patients with ongoing posaconazole prophylaxis received an initial empirical sirolimus dose reduction at 1 mg/day.
The median posaconazole concentration achieved during therapy was sufficient (40.5 mL/L) in 65% of patients, whereas 33% of them had median concentrations above 0.7 mL/L. The median number of posaconazole concentrations measured per patient was 14 (range, 2-55 observations). Among 32 patients with posaconazole concentrations measured in the early post-transplant period, 23 maintained a sufficient prophylactic concentration (40.5 mL/L). TDM was maintained within a prophylactic range in 68% of the patients with acute GvHD and 53% in chronic GvHD cases.
The coadministration of posaconazole and sirolimus was safe overall. Discontinuation was reported mainly in patients with documented IFI, who required a change of the antifungal drug. No adverse events potentially associated with sirolimus overexposure (that is, sinusoidal obstructive syndrome, sirolimus-related thrombotic microangiopathy, neuropathy) were reported, although one-third of patients experienced a transient and moderate elevation of sirolimus serum levels in the first week of coadministration. Sirolimus trough concentrations on discharge were within therapeutic range for the majority of patients.
In this analysis, which included a population at high risk for IFI, breakthrough fungal infections occurred in 14 cases (21%): 8 possible, 4 probable and 2 proven (Figure 1a) . Median posaconazole concentrations in these patients were significantly lower than those in patients who did not develop IFI (Figure 1b) .
The risk of developing IFI was influenced by type of prophylaxis, resulting in 12% and 39% of IFI during primary and secondary prophylaxis, respectively (P-value = 0.013; OR = 4.89, CI: 1.39-17.11). However, the factor most significantly and strongly associated with the risk of IFI development was insufficient posaconazole serum levels ( o0.5 mL/L), 5 especially in patients with intestinal GvHD and/or diarrhea, given the drug's reported limitation of the oral solution formulation (P-value o0.0001; OR = 35.14, CI: 6.43-192).
Antifungal prophylaxis in allo-HSCT recipients is a rapidly evolving field. Due to recent extension of HSCT to patients at high risk of IFI (high-risk diseases, older patients and/or with comorbidities) with novel HSCT platforms (novel conditioning regimens, haploidentical or cord blood HSCT, CD34+ stem cell selection/T-cell depletion in vitro or in vivo), 12 antifungal prophylaxis has been a 'moving target', so reaching a consensus has proved difficult. Thus, posaconazole has an important role as prophylactic and salvage treatment of IFIs, although its variable bioavailability remains an important clinical concern. Although TDM is widely used for other triazole antifungal agents, such as voriconazole, the need to monitor plasma posaconazole concentrations has remained contentious. 13 Interactions among azoles and immunosuppressive drugs are important in the clinical management of transplant recipients.
14 However, very little is known about the impact of posaconazole on sirolimus.
This retrospective study has identified important clinical implications for the use of posaconazole in combination with sirolimus after allogeneic HSCT in patients at high risk for IFI. Here, we confirmed good clinical efficacy and safety of antifungal prophylaxis with posaconazole, even during the most critical early post-transplant phase, acute and chronic GvHD. To the best of our knowledge, this is the first study that analyzes the impact of posaconazole on the management of sirolimus in the different phases of allo-HSCT, and also reports data on posaconazole TDM and clinical outcomes. Moreover, we include in the analysis HSCT recipients with gastrointestinal GvHD, in whom subtherapeutic Abbreviations: ATG = anti-thymocyte globulin; HCT-CI = hematopoietic cell transplant-comorbidity index; HL = Hodgkin's lymphoma; HSCT = hematopoietic stem cell transplantation; MDS = myelodysplastic syndrome; MM = multiple myeloma; MPD = myeloproliferative disorder; NHL = nonHodgkin's lymphoma; PTCy = post-transplant cyclophosphamide. Invasive aspergillosis was the most common infection (four cases), whereas invasive candidiasis (one case) and zygomycosis (one case) resulted uncommon. IFI were classified according to the standard definitions from the EORTC/MSG Consensus Group. 11 (b) The bottom panel represents the posaconazole TDM during prophylaxis and the development of breakthrough fungal infections. Posaconazole dose was considered 'sufficient' when more than 0.5 mL/L, and 'adequate' if the concentration is 40.7 mL/L, according to the majority of literature and center guidelines.
5 GvHD = graft versus host disease; IFI = invasive fungal infections; TDM = therapeutic drug monitoring.
posaconazole concentrations are common, supporting the need for TDM to ensure efficacious posaconazole exposure.
Our strategy was safe and well tolerated from a clinical perspective. Concurrent sirolimus and posaconazole use was feasible with close monitoring of sirolimus and posaconazole trough serum levels in the first month of coadministration. Sirolimus doses were reduced by 55-70% when posaconazole was introduced.
In addition, as it is difficult to isolate and predict the independent effect on sirolimus levels of posaconazole from that of other drugs and factors in such complex patients, it would also appear more cautious not only to automatically reduce the sirolimus dose in all cases upfront, but also to allow dosage changes to be guided by TDM.
Moreover, these results support a significant exposureresponse relationship between posaconazole concentration and prophylactic efficacy. Among patients who received prophylactic posaconazole, 14 patients (21%) developed a breakthrough fungal infection after allo-HSCT. The incidence of IFI was 5% in patients with adequate posaconazole serum levels (40.5 mL/L), supporting the utility of TDM in such conditions and generating interest for the use of the upcoming posaconazole tablets, known to improve drug bioavailability and potentially modify the use of TDM in allo-HSCT recipients. 15 
